P538: FAST-TRACK MEASURABLE RESIDUAL DISEASE DETECTION BY MULTIPARAMETRIC FLOW CYTOMETRY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

Autor: Maximilian Roehnert, Michael Kramer, Jonas Schadt, Philipp Ensel, Christoph Roellig, Johannes Schetelig, Friedrich Stoelzel, Richard Schlenk, Martin Bornhaueser, Malte von Bonin, Uta Oelschlaegel

Publikováno v: HemaSphere, Vol 7, p e175805c (2023)

Externí odkaz: https://doaj.org/article/1e675d38912848e18909005f52c3b21d

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial

Autor: Christoph Röllig, Lars Fransecky, Maher Hanoun, Björn Steffen, Sabrina Kraus, Christoph Schliemann, Annett Haake, Frank Fiebig, Sven Zukunft, Nael Alakel, Jan Moritz Middeke, Martin Bornhaeuser, Friedrich Stoelzel, Johannes Schetelig, Leo Ruhnke, Michael Kramer, Malte Von Bonin, Maximilian Alexander Röhnert, Uta Oelschlägel, Claudia D. Baldus, Hubert Serve, Martin Wermke

Publikováno v: Blood. 140:3327-3328

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b8988b82a26965c001d1e16408c266c4
https://doi.org/10.1182/blood-2022-159897

Allogeneic hematopoietic cell transplantation in patients ≤ 60 years with intermediate-risk acute myeloid leukemia in first remission - results of the randomized etal-1 trial

Autor: Hubert Serve, Mathias Haenel, Johanna Tischer, Martin Bornhaeuser, Christoph Schliemann, Karsten Spiekermann, Kerstin Schaefer-Eckart, Wolfgang E. Berdel, Lutz P. Mueller, Gesine Bug, Stefan Klein, Georg Lenz, Christoph Schmid, Dietrich W. Beelen, Edgar Jost, Nael Alakel, Markus Pfirrmann, Gerhard Ehninger, Matthias Stelljes, Wolf Roesler, Friedrich Stoelzel, Michael Kramer, Uwe Platzbecker, Christoph Röllig, Johannes Schetelig, Bertram Glass, Andreas Burchert

Allogeneic hematopoietic cell transplantation (HCT) offers the highest chance for cure in patients with adverse-risk acute myeloid leukemia (AML) when performed in first remission (CR1). In contrast, patients in CR1 with favorable risk do not seem to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56fc06634c9e3a329a614560de2b95ec
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/98269

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

Autor: Zeiser, R., von Bubnoff, N., Butler, J., Mohty, M., Niederwieser, D., Or, R., Szer, J., Wagner, E. M., Zuckerman, T., Mahuzier, B., Xu, J., Wilke, C., Gandhi, K. K., Socie, G, Sung-Soo, Yoon, Chulwon, Jung, Tobias, Gedde-Dahl, Marwan, Shaheen, Jose Antonio Perez Simon, Jose Valentin Garcia Gutierrez, Jaime Sanz Caballer, Rafael Duarte Palomino, David Valcarcel Ferreiras, Cristina Diaz de Heredia Rubio, Kwon, Mi, Maria Del Carmen Martinez Munoz, Soledad, Gonzalez, Matilde Rodriguez Ruiz, Inmaculada Heras Fernando, Maria Pascual Cascon, Ana Sastre Urgelles, Marta Gonzalez Vicent, Jose Maria Fernandez Navarro, Yvonne, Björk, Kristina, Carlson, Jih-Luh, Tang, Su-Peng, Yeh, Ronjon, Chakraverty, Robert, Wynn, Lajos, Floro, Brian Thomas Kornblit, Jason, Butler, David, Ritchie, John, Kwan, Jacqueline, Fleming, Duncan, Purtill, Georg, Hopfinger, Hildegard, Greinix, Johannes, Clausen, Dennis, Kim, Natasha, Kekre, Imran, Ahmad, Brian, Leber, Andrew, Daly, Gizelle, Popradi, Jennifer, White, Mohamed, Elemary, Gerard, Socie, Valérie, Coiteux, Patrice, Chevallier, Claude-Eric, Bulabois, Helene, Labussiere-Wallet, Mohamad, Mohty, Pierre-Simon, Rohrlich, Edouard, Forcade, Fabrice, Larosa, Sylvie, Francois, Stephanie N'Guyen Quoc, Marie-Therese, Rubio, Jean-Hughes, Dalle, Marie, Ouachee-Chardin, Benedicte, Bruno, Anne, Huynh, Nathalie, Fegueux, Jerome, Cornillon, Pascal, Turlure, Nikolas von Bubnoff, Georg-Nikolaus, Franke, Friedrich, Stoelzel, Matthias, Eder, Arne, Brecht, Nicolaus, Kroeger, Nina-Kristin, Steckel, Eva, Wagner, Guido, Kobbe, Wolfgang, Bethge, Matthias, Stelljes, Donald, Bunjes, Igor, Blau, Ingo, Mueller, Stefan, Klein, Christoph, Schmid, Lena, Oevermann, Herrad, Baurmann, Inken, Hilgendorf, Klaus Daniel Stachel, Yok-Lam, Kwong, Ron, Ram, Batya, Avni, Moshe, Yeshurun, Tsila, Zuckerman, Riccardo, Saccardi, Paolo, Corradini, Franco, Locatelli, Alessandro, Rambaldi, Andrea, Bacigalupo, Attilio, Olivieri, Francesca, Patriarca, Giovanni, Grillo, Francesca, Bonifazi, Edoardo, Lanino, Attilio, Rovelli, Benedetto, Bruno, Russo, Domenico, Maurizio, Musso, Marco, Zecca, Franca, Fagioli, Angelo Michele Carella, Stefania, Bregante, Roberto, Sorasio, Takanori, Teshima, Koichi, Miyamura, Kiyoshi, Ando, Hirohisa, Nakamae, Yoshinobu, Maeda, Tadakazu, Kondo, Masaya, Okada, Kazuhiko, Kakihana, Koji, Kato, Yasushi, Onishi, Kentaro, Fukushima, Shuichi, Taniguchi, Takehiko, Mori, Takayuki, Ishikawa, Yoshihiro, Inamoto, Kuball, J, A Lindemans, C, Jan, Vydra, Achilleas, Anagnostopoulos, Zubeyde, Ozkurt, Zafer, Gulbas, Seckin, Cagirgan, Sinem Civriz Bozdag, Penka, Ganeva, Dobrin, Konstantinov, Kazimierz, Halaburda, Jan, Zaucha, Gergely KrivÃ, N, Isabelina, Ferreira, Joao Forjaz de Lacerda, Alexey, Maschan, Elena, Parovichnikova

Acute graft-versus-host disease (GVHD) remains a major limitation of allogeneic stem-cell transplantation; not all patients have a response to standard glucocorticoid treatment. In a phase 2 trial, ruxolitinib, a selective Janus kinase (JAK1 and JAK2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4b695b267a2a6439599dcd2674f979a
http://hdl.handle.net/11379/531211

Gemtuzumab Ozogamicin Plus Midostaurin in Combination with Standard Intensive Induction Therapy in Newly Diagnosed AML: Results from a Phase-I Study

Autor: Christoph Schliemann, Lars Fransecky, Martin Bornhäuser, Theresa Kretschmann, Friedrich Stoelzel, Nael Alakel, Manja Reimann, Claudia D. Baldus, Sebastian Scholl, Maher Hanoun, Knut Wendelin, Martin Wermke, Kerstin Schäfer-Eckart, Richard Noppeney, Christoph Röllig, Björn-Niklas Heydrich, Jan-Henrik Mikesch, Frank Fiebig, Ulf Schnetzke

Publikováno v: Blood. 138:2324-2324

Background In newly diagnosed acute myeloid leukemia (AML) with FLT3 mutations (FLT3-mut), the tyrosine kinase inhibitor midostaurin (MIDO) in combination with intensive chemotherapy (IC) is considered standard of care (SoC). Subgroup analyses from t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::42dac885268f85a575ffe24f7825d6f2
https://doi.org/10.1182/blood-2021-150069